MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Gesloten

1.17 -6.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.16

Max

1.22

Belangrijke statistieken
By Trading Economics
Inkomsten	-51K -928K
EPS	-0.254
Werknemers	2
EBITDA	-51K -928K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-6.6M 4.8M
Vorige openingsprijs	7.57
Vorige sluitingsprijs	1.17

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 apr 2026, 17:04 UTC

Belangrijke Marktbewegers

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 apr 2026, 00:00 UTC

Winsten

Acquisities, Fusies, Overnames

Big Yachts, Big Bucks -- Barrons.com

10 apr 2026, 21:55 UTC

Acquisities, Fusies, Overnames

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 apr 2026, 21:01 UTC

Winsten

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

10 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

10 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 apr 2026, 20:31 UTC

Marktinformatie

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 apr 2026, 20:10 UTC

Acquisities, Fusies, Overnames

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 19:15 UTC

Marktinformatie

Global Energy Roundup: Market Talk

10 apr 2026, 19:15 UTC

Marktinformatie

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 apr 2026, 19:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

10 apr 2026, 19:08 UTC

Marktinformatie

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 apr 2026, 18:38 UTC

Marktinformatie

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 apr 2026, 18:25 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Precious Metals Finish With Weekly Gains -- Market Talk

10 apr 2026, 18:05 UTC

Marktinformatie

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 apr 2026, 17:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 apr 2026, 17:26 UTC

Winsten

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 apr 2026, 17:10 UTC

Marktinformatie

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 apr 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 apr 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 apr 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

10 apr 2026, 16:12 UTC

Winsten

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 apr 2026, 16:11 UTC

Winsten

Partners Group: Traditional Programs Contributed $3.3B

10 apr 2026, 16:10 UTC

Winsten

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 apr 2026, 16:10 UTC

Winsten

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 apr 2026, 16:10 UTC

Winsten

Partners Group 1Q New Client Demand $8.3B

10 apr 2026, 16:09 UTC

Winsten

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 apr 2026, 15:54 UTC

Acquisities, Fusies, Overnames

Plenitude Completes Acquisition of Acea Energia

10 apr 2026, 15:38 UTC

Marktinformatie

Global Energy Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.